Zobrazeno 1 - 10
of 358
pro vyhledávání: '"recombinant human granulocyte colony stimulating factor"'
Autor:
Ting Zhao, Huanhuan Xu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundRecombinant human granulocyte-colony stimulating factors (G-CSF)-induced aortitis is a rare but particularly serious adverse event, commonly seen in cancer patients undergoing chemotherapy. The aim of this article is to clarify the clinical
Externí odkaz:
https://doaj.org/article/25e08c56536c4864828eb92db6967888
Autor:
Jun-Jun Zhang, Ping Yu, Hui Dang, Cheng-Shuang Feng, Xiu-Jiang Long, Wen-Fa Huang, Lei Wang, Jie-Ling Li, Guo-Liang Tian, Jia-Quan Wen, Jun-Hui Mei, Yu-Xiang Li
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Patients with hematological malignancies received multiple hypodermic injections of recombinant human granulocyte colony-stimulating factor. Procedural pain is one of the most common iatrogenic causes of pain in patients with hema
Externí odkaz:
https://doaj.org/article/163f62f18611470e9aa3a84349141067
Autor:
Shuya Qi, Lixing Liu
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e33074- (2024)
Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is an effective treatment for chemotherapy-induced neutropenia. However, it can also induce various adverse effects, including fever, bone pain, and other discomforts ari
Externí odkaz:
https://doaj.org/article/3d9855c219464b1b8f4bac017bbbf174
Autor:
Jun Wang, Baosheng Li
Publikováno v:
Precision Radiation Oncology, Vol 7, Iss 3, Pp 150-159 (2023)
Abstract Neutropenia is the most common hematological toxicity of concurrent chemoradiotherapy (CCRT), and leads to subsequent treatment delays and/or dose reductions. Neutropenia often advances to febrile neutropenia and serious infections, which ca
Externí odkaz:
https://doaj.org/article/7b4b2b220e5c4a77814a69fbe7dd9322
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 12 (2024)
The clinical application of the recombinant human granulocyte colony-stimulating factor (rhG-CSF) is restricted by its short serum half-life. Herein, site-selective modification of the N-terminus of rhG-CSF with PAL-PEG3-Ph-CHO was used to develop a
Externí odkaz:
https://doaj.org/article/5d9f6ef166334177ba7a38d80d4868b0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yong Wang, Chen Fang, Renfang Chen, Shangkun Yuan, Lin Chen, Xiaotong Qiu, Xiaoying Qian, Xinwei Zhang, Zhehao Xiao, Qian Wang, Biqi Fu, Xiaoling Song, Yong Li
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Recombinant human granulocyte colony-stimulating factor (rhG-CSF) reduces neutropenia events and is widely used in cancer patients receiving chemotherapy. However, the effects of rhG-CSF on distant organ metastasis (DOM) in non-sm
Externí odkaz:
https://doaj.org/article/033b751fadda43128adc075118bcd415
Autor:
Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang
Publikováno v:
Radiation Medicine and Protection, Vol 3, Iss 2, Pp 81-85 (2022)
Objective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization r
Externí odkaz:
https://doaj.org/article/9ad928adad6a4bb0bdc8f93cb41c9c2a
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 117-125 (2022)
Abstract Background NCCN guidelines recommend a dose of 100 μg/kg or a fixed dose of 6 mg pegylated recombinant human granulocyte colony‐stimulating factor (PEG rhG‐CSF) for chemotherapy‐induced neutropenia. However, a single dose of 60 μg/kg
Externí odkaz:
https://doaj.org/article/1b22a0812caa4b21b6a0693710d80d0a